ES2170853T3 - Nanosferas que comprenden un polisacarido biocompatible. - Google Patents

Nanosferas que comprenden un polisacarido biocompatible.

Info

Publication number
ES2170853T3
ES2170853T3 ES96909138T ES96909138T ES2170853T3 ES 2170853 T3 ES2170853 T3 ES 2170853T3 ES 96909138 T ES96909138 T ES 96909138T ES 96909138 T ES96909138 T ES 96909138T ES 2170853 T3 ES2170853 T3 ES 2170853T3
Authority
ES
Spain
Prior art keywords
microspheres
preparation
biocompatible
polisacaride
nanospheres
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96909138T
Other languages
English (en)
Inventor
Paolo Pallado
Luca Benedetti
Lanfranco Callegaro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anika Therapeutics SRL
Original Assignee
Fidia Advanced Biopolymers SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT95PD000065A external-priority patent/IT1281857B1/it
Priority claimed from ITPD960021 external-priority patent/IT1287194B1/it
Application filed by Fidia Advanced Biopolymers SRL filed Critical Fidia Advanced Biopolymers SRL
Application granted granted Critical
Publication of ES2170853T3 publication Critical patent/ES2170853T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Materials For Medical Uses (AREA)

Abstract

SE PREPARAN MICROESFERAS, QUE POSEEN UN TAMAÑO INFERIOR A 1 {MI} Y QUE COMPRENDEN UN POLIMERO DE POLISACARIDO BIOCOMPATIBLE, MEDIANTE UN PROCESO QUE COMPRENDE LA PRECIPITACION DEL POLIMERO INDUCIDA MEDIANTE UN ANTISOLVENTE SUPERCRITICO (SAS). ESTAS MICROSFERAS SE EMPLEAN COMO AGENTES DE VEHICULACION O VEHICULOS EN LA PREPARACION DE COMPOSICIONES FARMACEUTICAS ADMINISTRABLES MEDIANTE RUTA ORAL, NASAL, PULMONAR, VAGINAL O RECTAL. ESTAS MICROESFERAS PUEDEN SER UTILIZADAS TAMBIEN CON VENTAJA COMO AGENTES DE VEHICULACION O VEHICULOS EN LA PREPARACION DE COMPOSICIONES FARMACEUTICAS PARA EL TRATAMIENTO DE ENFERMEDADES HUMANAS ASOCIADAS CON DEFECTOS GENICOS, PARA LA PREPARACION DE ELEMENTOS DE DIAGNOSTICO Y EN LA INDUSTRIA AGROALIMENTARIA.
ES96909138T 1995-03-28 1996-03-26 Nanosferas que comprenden un polisacarido biocompatible. Expired - Lifetime ES2170853T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IT95PD000065A IT1281857B1 (it) 1995-03-28 1995-03-28 Processo per la preparazione di microsfere mediante l'impiego di fluidi supercritici.
ITPD960021 IT1287194B1 (it) 1996-02-05 1996-02-05 Processo per la preparazione di microsfere mediante l'impiego di fluidi supercritici
PCT/EP1996/001354 WO1996029998A1 (en) 1995-03-28 1996-03-26 Nanospheres comprising a biocompatible polysaccharide
US08/938,288 US6214384B1 (en) 1995-03-28 1997-09-26 Nanosheres comprising a biocompatible polysaccharide

Publications (1)

Publication Number Publication Date
ES2170853T3 true ES2170853T3 (es) 2002-08-16

Family

ID=27274135

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96909138T Expired - Lifetime ES2170853T3 (es) 1995-03-28 1996-03-26 Nanosferas que comprenden un polisacarido biocompatible.

Country Status (8)

Country Link
US (2) US6214384B1 (es)
EP (1) EP0817620B1 (es)
AT (1) ATE212545T1 (es)
AU (1) AU695207B2 (es)
CA (1) CA2216919C (es)
DE (1) DE69618938T2 (es)
ES (1) ES2170853T3 (es)
WO (1) WO1996029998A1 (es)

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6270795B1 (en) 1995-11-09 2001-08-07 Microbiological Research Authority Method of making microencapsulated DNA for vaccination and gene therapy
DE69608122T3 (de) 1995-11-09 2011-06-16 Microbiological Research Authority Camr, Salisbury Mikroverkapselte dna zur impfung und gentherapie
US6096291A (en) * 1996-12-27 2000-08-01 Biovector Therapeutics, S.A. Mucosal administration of substances to mammals
US5783567A (en) * 1997-01-22 1998-07-21 Pangaea Pharmaceuticals, Inc. Microparticles for delivery of nucleic acid
DE19711393C1 (de) * 1997-03-19 1998-08-13 Fraunhofer Ges Forschung Verfahren zum Mikroverkapseln von Partikeln
CA2303268A1 (en) 1997-06-13 1998-12-17 Scott Walsh Therapeutic nanospheres
US6844004B2 (en) 1997-08-15 2005-01-18 Board Of Regents, The University Of Texas System Topical formulations of natamycin/pimaricin
US6045815A (en) 1997-08-15 2000-04-04 Board Of Regents, The University Of Texas System Parenteral pimaricin as treatment of systemic infections
JP2002506876A (ja) * 1998-03-18 2002-03-05 ユニバーシティ テクノロジー コーポレーション 非晶質ポリマーを含む持続放出性組成物
US7022683B1 (en) 1998-05-13 2006-04-04 Carrington Laboratories, Inc. Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
US6406719B1 (en) 1998-05-13 2002-06-18 Microbiological Research Authority Encapsulation of bioactive agents
GB9810236D0 (en) 1998-05-13 1998-07-08 Microbiological Res Authority Improvements relating to encapsulation of bioactive agents
US6824793B1 (en) 1998-06-01 2004-11-30 Chiron Corporation Use of hyaluronic acid polymers for mucosal delivery of vaccine antigens and adjuvants
US6548302B1 (en) 1998-06-18 2003-04-15 Johns Hopkins University School Of Medicine Polymers for delivery of nucleic acids
US6916490B1 (en) 1998-07-23 2005-07-12 UAB Research Center Controlled release of bioactive substances
SE9804000D0 (sv) * 1998-11-23 1998-11-23 Astra Ab New composition of matter
WO2000050078A1 (en) 1999-02-26 2000-08-31 Chiron Corporation Use of bioadhesives and adjuvants for the mucosal delivery of antigens
IT1306643B1 (it) * 1999-04-08 2001-10-02 Fidia Advanced Biopolymers Srl Processo per la preparazione dei composti autoreticolati dell'acidoialuronico e dei suoi derivati ottenibili mediante la tecnica
IT1306644B1 (it) 1999-04-08 2001-10-02 Fidia Advanced Biopolymers Srl Strutture tridimensionali comprendenti derivati dell'acido ialuronicoottenibili mediante la tecnica antisolvente supercritico.
FR2797398B1 (fr) * 1999-08-11 2002-10-18 Mainelab Microparticules pour administration pulmonaire
SE9904121D0 (sv) * 1999-11-15 1999-11-15 Gustaf Jederstroem Hydrophobe biomolecular structure
GB9927011D0 (en) * 1999-11-16 2000-01-12 Advanced Phytonics Ltd Method for the production of particles
CH694686A5 (it) * 2000-03-04 2005-06-15 Eco2 Sa Prodotto di micronizzazione di sostanze farmaceutiche.
US9522217B2 (en) 2000-03-15 2016-12-20 Orbusneich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods for using same
AU2001245734A1 (en) 2000-03-15 2001-09-24 Orbus Medical Technologies Inc. Coating that promotes endothelial cell adherence
US8088060B2 (en) 2000-03-15 2012-01-03 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US8460367B2 (en) 2000-03-15 2013-06-11 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
IT1318404B1 (it) * 2000-03-17 2003-08-25 Eurand Int Processo per la preparazione di formulazioni a rilascio accelerato conimpiego di fluidi compressi.
FR2815540B1 (fr) † 2000-10-19 2005-06-10 Separex Sa Procede de fabrication de tres fines particules constituees d'un principe insere dans une molecule hote
US20030096013A1 (en) * 2000-12-22 2003-05-22 Jane Werling Preparation of submicron sized particles with polymorph control
US9700866B2 (en) * 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US6977085B2 (en) 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US7193084B2 (en) * 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US7037528B2 (en) 2000-12-22 2006-05-02 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US6884436B2 (en) 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US20050048126A1 (en) * 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US20040256749A1 (en) * 2000-12-22 2004-12-23 Mahesh Chaubal Process for production of essentially solvent-free small particles
US6777000B2 (en) * 2001-02-28 2004-08-17 Carrington Laboratories, Inc. In-situ gel formation of pectin
US7494669B2 (en) * 2001-02-28 2009-02-24 Carrington Laboratories, Inc. Delivery of physiological agents with in-situ gels comprising anionic polysaccharides
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
BR0212833A (pt) * 2001-09-26 2004-10-13 Baxter Int Preparação de nanopartìculas de tamanho submìcron através de dispersão e de remoção de solvente ou de fase lìquida
US7112340B2 (en) * 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
US7094369B2 (en) 2002-03-29 2006-08-22 Scimed Life Systems, Inc. Processes for manufacturing polymeric microspheres
US7462366B2 (en) 2002-03-29 2008-12-09 Boston Scientific Scimed, Inc. Drug delivery particle
US7131997B2 (en) * 2002-03-29 2006-11-07 Scimed Life Systems, Inc. Tissue treatment
US7053134B2 (en) * 2002-04-04 2006-05-30 Scimed Life Systems, Inc. Forming a chemically cross-linked particle of a desired shape and diameter
US20040076582A1 (en) * 2002-08-30 2004-04-22 Dimatteo Kristian Agent delivery particle
US7842377B2 (en) * 2003-08-08 2010-11-30 Boston Scientific Scimed, Inc. Porous polymeric particle comprising polyvinyl alcohol and having interior to surface porosity-gradient
US7449236B2 (en) * 2002-08-09 2008-11-11 Boston Scientific Scimed, Inc. Porous polymeric particle comprising polyvinyl alcohol and having interior to surface porosity-gradient
US8012454B2 (en) 2002-08-30 2011-09-06 Boston Scientific Scimed, Inc. Embolization
US6966990B2 (en) 2002-10-11 2005-11-22 Ferro Corporation Composite particles and method for preparing
US7883490B2 (en) * 2002-10-23 2011-02-08 Boston Scientific Scimed, Inc. Mixing and delivery of therapeutic compositions
US7588825B2 (en) * 2002-10-23 2009-09-15 Boston Scientific Scimed, Inc. Embolic compositions
US6931888B2 (en) 2003-02-07 2005-08-23 Ferro Corporation Lyophilization method and apparatus for producing particles
US7083748B2 (en) * 2003-02-07 2006-08-01 Ferro Corporation Method and apparatus for continuous particle production using supercritical fluid
US20060008531A1 (en) * 2003-05-08 2006-01-12 Ferro Corporation Method for producing solid-lipid composite drug particles
US7976823B2 (en) 2003-08-29 2011-07-12 Boston Scientific Scimed, Inc. Ferromagnetic particles and methods
US7901770B2 (en) 2003-11-04 2011-03-08 Boston Scientific Scimed, Inc. Embolic compositions
US9066912B2 (en) * 2003-11-17 2015-06-30 Ethicon, Inc. Drug-enhanced adhesion prevention
JP2007520555A (ja) * 2004-02-05 2007-07-26 バクスター・インターナショナル・インコーポレイテッド 自己安定化剤の使用により調製された分散剤
US8277831B2 (en) * 2004-02-17 2012-10-02 Advanced Technologies And Regenerative Medicine, Llc. Drug-enhanced adhesion prevention
US7736671B2 (en) 2004-03-02 2010-06-15 Boston Scientific Scimed, Inc. Embolization
US8173176B2 (en) 2004-03-30 2012-05-08 Boston Scientific Scimed, Inc. Embolization
US20050238870A1 (en) * 2004-04-22 2005-10-27 Marcia Buiser Embolization
TW200605910A (en) 2004-04-30 2006-02-16 Orbus Medical Technologies Inc Medical device with coating for capturing genetically-altered cells and methods for using same
US7311861B2 (en) 2004-06-01 2007-12-25 Boston Scientific Scimed, Inc. Embolization
US7384879B2 (en) 2004-09-27 2008-06-10 Auburn University Selection and deposition of nanoparticles using CO2-expanded liquids
FR2880272A1 (fr) * 2005-01-04 2006-07-07 Jean Marc Ruiz Preparation contenant des microparticules d'un sel de polymere insoluble portant un principe actif, ainsi que son procede de fabrication
US7727555B2 (en) * 2005-03-02 2010-06-01 Boston Scientific Scimed, Inc. Particles
US7858183B2 (en) * 2005-03-02 2010-12-28 Boston Scientific Scimed, Inc. Particles
US7963287B2 (en) 2005-04-28 2011-06-21 Boston Scientific Scimed, Inc. Tissue-treatment methods
WO2006138202A2 (en) * 2005-06-14 2006-12-28 Baxter International Inc. Pharmaceutical formulations for minimizing drug-drug interactions
US20060280787A1 (en) * 2005-06-14 2006-12-14 Baxter International Inc. Pharmaceutical formulation of the tubulin inhibitor indibulin for oral administration with improved pharmacokinetic properties, and process for the manufacture thereof
US20070004973A1 (en) * 2005-06-15 2007-01-04 Tan Sharon M L Tissue treatment methods
HUE029021T2 (en) 2005-06-21 2017-02-28 Xoma (Us) Llc IL-1beta-binding antibodies and fragments thereof
US9463426B2 (en) * 2005-06-24 2016-10-11 Boston Scientific Scimed, Inc. Methods and systems for coating particles
US20070134341A1 (en) * 2005-11-15 2007-06-14 Kipp James E Compositions of lipoxygenase inhibitors
US7501179B2 (en) * 2005-12-21 2009-03-10 Boston Scientific Scimed, Inc. Block copolymer particles
US7947368B2 (en) 2005-12-21 2011-05-24 Boston Scientific Scimed, Inc. Block copolymer particles
US20070142560A1 (en) * 2005-12-21 2007-06-21 Young-Ho Song Block copolymer particles
WO2007123793A2 (en) 2006-04-04 2007-11-01 Stc.Unm Swellable particles for drug delivery
EP3124045A3 (en) 2006-12-20 2017-05-03 Xoma (Us) Llc Treatment of il-1 beta related diseases
WO2008080047A2 (en) * 2006-12-23 2008-07-03 Baxter International Inc. Magnetic separation of fine particles from compositions
US20080293814A1 (en) * 2007-05-22 2008-11-27 Deepak Tiwari Concentrate esmolol
US8426467B2 (en) * 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
US8722736B2 (en) * 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
AU2008279129A1 (en) * 2007-07-24 2009-01-29 Nexbio, Inc. Technology for the preparation of microparticles
SI2391650T1 (sl) 2007-12-20 2015-03-31 Xoma (Us) Llc Postopki za zdravljenje protina
US8215489B1 (en) 2008-10-31 2012-07-10 Auburn University Method and apparatus for physical separation of different sized nanostructures
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
ITRM20110008A1 (it) * 2011-01-12 2012-07-13 Alfonso Barbarisi Procedimento per la partecipazione di nanoparticelle reticolate a base di estere benzilico dell'acido ialuronico da utilizzare come vettori per il rilascio controllato di principi attivi
WO2012119980A1 (en) 2011-03-04 2012-09-13 Institut National De La Sante Et De La Recherche Medicale (Inserm) Particles containing a growth factor, and uses thereof
TWI419701B (zh) * 2011-11-08 2013-12-21 包覆生長因子之多醣體微粒子
WO2013096516A1 (en) 2011-12-19 2013-06-27 Xoma Technology Ltd. Methods for treating acne
CA2863224A1 (en) 2012-01-09 2013-07-18 The Scripps Research Institute Ultralong complementarity determining regions and uses thereof
JP2015509091A (ja) 2012-01-09 2015-03-26 ザ スクリプス リサーチ インスティテュート ヒト化抗体
US9598503B2 (en) 2012-04-18 2017-03-21 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
EP2866792A4 (en) 2012-06-28 2016-08-17 Ansun Biopharma Inc MICROPARTICLE FORMULATIONS FOR DELIVERY TO LOWER AND CENTRAL RESPIRATORY PATHS AND METHOD OF PREPARING THEM
CA2918370A1 (en) 2013-07-18 2015-01-22 Fabrus, Inc. Humanized antibodies with ultralong complementarity determining regions
WO2015017146A2 (en) 2013-07-18 2015-02-05 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
JP6822839B2 (ja) 2013-09-13 2021-01-27 ザ・スクリップス・リサーチ・インスティテュート 修飾された治療剤、及びその組成物
CN105829349B (zh) 2013-10-15 2023-02-03 斯克利普斯研究所 肽嵌合抗原受体t细胞开关和其用途
CN105814083A (zh) 2013-10-15 2016-07-27 加州生物医学研究所 嵌合抗原受体t细胞开关和其用途
KR102455171B1 (ko) 2013-12-18 2022-10-14 더 스크립스 리서치 인스티튜트 변형된 치료제, 스테이플드 펩티드 지질 접합체, 및 이의 조성물
US10800828B2 (en) 2015-03-26 2020-10-13 The Scripps Research Institute Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer
US11091546B2 (en) 2015-04-15 2021-08-17 The Scripps Research Institute Optimized PNE-based chimeric receptor T cell switches and uses thereof
WO2016205488A1 (en) 2015-06-17 2016-12-22 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
EP3529268B1 (en) 2016-10-19 2025-02-26 The Scripps Research Institute Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof
EP3807644A4 (en) 2018-06-12 2022-07-06 Angiex, Inc. ANTIBODY-OLIGONUCLEOTIDE CONJUGATES
CA3149494A1 (en) 2019-08-12 2021-02-18 Purinomia Biotech, Inc. Methods and compositions for promoting and potentiating t-cell mediated immune responses through adcc targeting of cd39 expressing cells
CN115551594A (zh) 2019-10-24 2022-12-30 米诺陶治疗公司 经细胞因子修饰的嵌合抗体及其使用方法
MX2022006861A (es) 2019-12-04 2022-07-11 Scripps Research Inst Agonistas del receptor glp2 y metodos de uso.
US20250197525A1 (en) 2021-04-28 2025-06-19 Minotaur Therapeutics, Inc. Humanized chimeric bovine antibodies and methods of use
KR20240032010A (ko) 2021-06-09 2024-03-08 더 스크립스 리서치 인스티튜트 장기 지속형 이중 gip/glp-1 펩타이드 접합체 및 사용 방법
IL316289A (en) 2022-04-29 2024-12-01 Purinomia Biotech Inc Methods and compositions for treating diseases and disorders driven by eosinophils

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3185625A (en) * 1961-11-08 1965-05-25 Brown Ethan Allan Injectionable substances
EP0093757A1 (en) * 1981-11-12 1983-11-16 Ulf SCHRÖDER Intravascularly administrable, magnetically responsive nanosphere or nanoparticle, a process for the production thereof, and the use thereof
US5129877A (en) * 1988-04-29 1992-07-14 University Of Georgia Research Foundation, Inc. Receptor-mediated delivery system
AU624421B2 (en) * 1988-10-05 1992-06-11 Pharmacia & Upjohn Company Finely divided solid crystalline powders via precipitation into an anti-solvent
IT1247472B (it) * 1991-05-31 1994-12-17 Fidia Spa Processo per la preparazione di microsfere contenenti componenti biologicamente attivi.
US5607691A (en) * 1992-06-12 1997-03-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
FR2692168B1 (fr) * 1992-06-16 1995-03-24 Centre Nat Rech Scient Préparation et utilisation de nouveaux systèmes colloïdaux dispersibles à base de cyclodextrine, sous forme de nanosphères.
EP0668073B1 (en) * 1994-02-21 1999-04-14 Takeda Chemical Industries, Ltd. Polyester matrix for a pharmaceutical sustained-release preparation
US5565188A (en) * 1995-02-24 1996-10-15 Nanosystems L.L.C. Polyalkylene block copolymers as surface modifiers for nanoparticles

Also Published As

Publication number Publication date
CA2216919C (en) 2007-09-18
DE69618938T2 (de) 2002-10-31
WO1996029998A1 (en) 1996-10-03
ATE212545T1 (de) 2002-02-15
AU695207B2 (en) 1998-08-06
AU5274996A (en) 1996-10-16
CA2216919A1 (en) 1996-10-03
EP0817620A1 (en) 1998-01-14
US6541035B1 (en) 2003-04-01
EP0817620B1 (en) 2002-01-30
DE69618938D1 (de) 2002-03-14
US6214384B1 (en) 2001-04-10

Similar Documents

Publication Publication Date Title
ES2170853T3 (es) Nanosferas que comprenden un polisacarido biocompatible.
ATE205086T1 (de) Verwendung von dem chelatbildner clioquinol zur herstellung eines arzneimittelszur behandlung von alzheimerschen krankheit
ATE199060T1 (de) Tierarzneimittel, das einen protonenpumpeninhibitor enthält
HUT60630A (en) Process or producing peroral pharmaceutical compositions suitable for treating internal diseases of inflammatory nature
NO950784L (no) Fettsyrederivater
BR0015506A (pt) Conjugados de interferon gama, métodos para sua preparação, composições farmacêuticas que compreendem ás moléculas e seu uso no tratamento de doenças
SE9704833D0 (sv) New formulation
NO922936L (no) Fremstilling av fettsyremedikamenter
ES2194727T3 (es) Estructuras tridimensionales que contienen derivados del acido hialuronico obtenidos por la tecnica del antidisolvente supercritico.
GR3031250T3 (en) Methods of diagnosing and treating preeclampsia
DE69033970D1 (de) Huperzin a analoge verbindungen
DE69824748D1 (de) Pharmazeutische zusammensetzung für die behandlung von enzündlichen darmerkrankungen
ITRM920900A0 (it) Formulazione proteica coadiuvante nella prevenzione e cura delle parodontiti e di altre patologie batteriche del cavo orale.
DE69517191D1 (de) Wasserlösliche derivate epipodophyllotoxine, verfahren zu ihrer herstellung, ihre verwendung als medikament und ihre verwendung zur herstellung eines antikrebsmittels
ATE226069T1 (de) Verwendung von alkanoyl-l-carnitinen zur herstellung eines arzneimittels zur behandlung von entzündlichen darmerkrankungen
DE69733169D1 (de) Verwendung von Alpha-1-Adrenorezeptor-Antagonisten zur Herstellung eines Medikaments für die Vorbeugung und die Behandlung von Krebs
ES2110258T3 (es) Derivados de 1,3,5(10)-estratrieno activos por via oral.
DE69012386D1 (de) Impfstoff und Diagnostikum für den Schweine-Cholera-Virus.
DE69003960D1 (de) Die Verwendung von deacetyliertem Chitin zur Herstellung eines Medikamentes für die Behandlung von entzündliche Krankheiten.
Pincus et al. Norflox or Norflex?
DE3878154D1 (de) Oral anzuwendende arzneiform zur einmal taeglichen behandlung der hypertonie mit diltiazemhydrochlorid.
NO960347D0 (no) Anvendelse av benzydamid ved behandling av patologiske tilstander forårsaket av TNF
NO911460D0 (no) Fremgangsmaate og apparat for redusere konsentrasjonen av hydroxylioner i vandige opploesninger av hydroxyl- og perhydroxylioner.
HUP0102116A2 (hu) Paroxetin-aszkorbát, eljárás az előállítására és gyógyászati alkalmazása
BG101173A (en) Vaccine against pasteurellosis and haemorrhagic disease in rabbits

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 817620

Country of ref document: ES